Back to Search Start Over

Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors

Authors :
S.O. Song
Da Hea Seo
Soon-Sun Hong
Bo Yeon Kim
Jung Hyun Noh
Dae Jung Kim
Chul-Hee Kim
S.O. Park
K.-S. Kim
Ji A Seo
Jun-Won Yun
Ja Young Jeon
S.-K. Kim
Source :
Diabetes & Metabolism. 45:453-457
Publication Year :
2019
Publisher :
Elsevier BV, 2019.

Abstract

Aim This study investigated the clinical characteristics of diabetic ketoacidosis (DKA) and compared the DKA characteristics between patients treated with and without SGLT2 inhibitors. Methods Data were collected from patients aged ≥ 18 years admitted for DKA at nine centres in Korea between September 2014 and April 2017. The electronic medical records of these subjects were retrospectively reviewed. Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared. Results During the study, the main subtype of DKA episodes (n = 523) was identified as type 2 diabetes (51%). Average hospitalization duration was 11 days, and average intensive care unit (ICU) time was 2.5 days. The in-hospital mortality rate was 3%, but no users of SGLT2 inhibitors died during DKA treatment. In patients taking SGLT2 inhibitors (n = 15), DKA manifested at 124 days, on average, after starting the inhibitors (range: 7–380 days). Also, SGLT2 inhibitors users had significantly lower plasma glucose levels (413 mg/dL) compared with non-users (554 mg/dL), and longer ICU stays (4 vs. 2 days; P = 0.019). Conclusion In this report of recent data on the clinical features of DKA in Korea, patients using SGLT2 inhibitors needed longer treatment in ICUs compared with non-users and had lower levels of blood glucose, whereas DKA associated with SGLT2 inhibitors was rare.

Details

ISSN :
12623636
Volume :
45
Database :
OpenAIRE
Journal :
Diabetes & Metabolism
Accession number :
edsair.doi.dedup.....bfd1cb911b44c89d96aeca4e909b7213
Full Text :
https://doi.org/10.1016/j.diabet.2019.01.001